Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valchlor

- PMLiVE

Celgene bid to push Revlimid beyond myeloma blocked again

Cancer treatment fails phase III trial in lymphoma

- PMLiVE

J&J back in frame to buy Actelion after Sanofi talks break down

Parties now in exclusive negotiations about a possible deal

Deal Watch November 2016

Actelion, Allergan, Johnson & Johnson, Novartis and more feature in this month's pharma deals round-up

Eli Lilly HQ

Lilly nears EU approval of arthritis drug baricitinib

On course for early 2017 verdict, setting up challenge to Pfizer’s Xeljanz

Actelion HQ Switzerland

J&J abandons talks with Actelion as another suitor circles

Biotech said to be holding out for a higher offer as speculation of Sanofi interest builds

Actelion HQ Switzerland

Resurgent Actelion catches J&J’s eye

Confirms talks of possible take over after Uptravi sees ‘outstanding’ sales

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

- PMLiVE

CHMP recommends Merck & Co’s Lantus biosimilar

Also backs two biosimilar versions of Lilly’s osteoporosis therapy Forteo

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

- PMLiVE

CHMP backs Intercept’s rare liver disease drug

Ocaliva on track for EU approval as analysts predict blockbuster sales

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

- PMLiVE

Kite Pharma soars after positive CAR-T data in lymphoma

Looks to become first marketed CAR-T drug as phase II results pave way for US filing

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links